Profil
Ben is a global biopharma business development professional who has been strategic advisor to leading companies, institutions and start-ups.
Prior to joining Novatio, Ben ran business development for a U.S.
technology accelerator, ACTUS Biotechnologies, where he played an integral role in strategic partnering for certain transdermal and tumor-targeting technologies licensed from UCSB and Sanford Burnham by its portfolio companies, Convoy and EnduRx, securing a key licensing deal in 2013.
Since 2005, Ben has run a Hong Kong-based consulting firm, Nexanova Ltd, and worked on over 40 projects covering oncology, cardiovascular disease, neurology, dermatology and infectious diseases for leading bio-pharma clients, including Debiopharm, Green Cross, and Samyang Pharmaceutical.
He has also worked closely with universities and their spin-off companies in Hong Kong and Korea, including HKUST, CUHK, SNU, and Yonsei.
Prior to entering the bio-pharma industry, Ben was China Business Development Manager for the animal nutrition division of Associated British Foods plc, where he specialized in acquisitions and set up two joint ventures in China.
Ben holds an MA (Hons) degree in Chinese and Japanese from Edinburgh University and an MBA from Manchester Business School.
He is fluent in Mandarin.
Postes actifs de Ben Walker
| Sociétés | Poste | Début |
|---|---|---|
Novatio Ventures
 Novatio Ventures Investment ManagersFinance Novatio Ventures (Novatio Ventures) is a venture capital firm founded in 2015 by Peng Fu. The firm is headquartered in Toronto, Canada. | Private Equity Investor | 01/01/2015 |
Anciens postes connus de Ben Walker
| Sociétés | Poste | Fin |
|---|---|---|
Convoy Therapeutics, Inc.
 Convoy Therapeutics, Inc. BiotechnologyHealth Technology Convoy Therapeutics, Inc. develops and commercializes drug delivery technologies. Its platform technology allows large and small molecules to penetrate and remain localized in the skin. The company consists of preclinical programs in psoriasis, eczema, acne and pigmentation, and one platform-developed asset being commercialized through partners and a second asset poised for internal clinical development. Convoy Therapeutics was founded in 2011 and is headquartered in Oro Valley, AZ. | Corporate Officer/Principal | 01/10/2014 |
Formation de Ben Walker
| The University of Manchester | Graduate Degree |
| The University of Edinburgh | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Convoy Therapeutics, Inc.
Convoy Therapeutics, Inc. BiotechnologyHealth Technology Convoy Therapeutics, Inc. develops and commercializes drug delivery technologies. Its platform technology allows large and small molecules to penetrate and remain localized in the skin. The company consists of preclinical programs in psoriasis, eczema, acne and pigmentation, and one platform-developed asset being commercialized through partners and a second asset poised for internal clinical development. Convoy Therapeutics was founded in 2011 and is headquartered in Oro Valley, AZ. | Health Technology |
Novatio Ventures
Novatio Ventures Investment ManagersFinance Novatio Ventures (Novatio Ventures) is a venture capital firm founded in 2015 by Peng Fu. The firm is headquartered in Toronto, Canada. | Finance |
